Amgen and Xencor have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.
Chris Lange The short interest data are out for the August 31 settlement date. Short interest in the selected biotech stocks increased across the board for this settlement date.
Tuesday’s top analyst upgrades, downgrades and initiations include Amgen, Dow Chemical, Fitbit, Office Depot, SanDisk, Wells Fargo and Yum! Brands.
Amgen has the potential to disrupt the market for cholesterol drugs with the newest addition to its drug portfolio.
Chris Lange The short interest data are out for the August 14 settlement date. Biotech companies are considered a riskier group of stocks.
The short interest data are out for the July 31 settlement date, and overall, short interest in the selected biotech stocks backed off for this period.
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of August and added some color.
According to Argus, second-quarter earnings, along with a strong pipeline and general outlook, have positioned Amgen to take the market by storm.
Chris Lange ThinkstockAmgen Corp. (NASDAQ: AMGN) reported fiscal second quarter 2015 earnings Thursday afternoon after equity markets had closed. The biotech firm posted adjusted earnings per share (EPS) of $2.57 on revenues of $5.37…
Paul Ausick ThinkstockAmgen Inc. (NASDAQ: AMGN) is scheduled to report its earnings after the markets close on Thursday. There are consensus estimates from Thomson Reuters that call for $2.43 in earnings per share (EPS)…
Chris Lange ThinkstockThe short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or…
ThinkstockPharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc. (NYSE: MRK)…
A new research report from Cowen focuses on the top biotech stocks to buy before second-quarter earnings are reported.
24/7 Wall St. has reviewed the short interest in top biotech companies, without focusing on speculative companies.
None of these stocks are on the momentum traders' radar, and that is exactly what prudent growth investors need now.
